Ju-Tao Guo

Enantigen Therapeutics, Inc.

$1,831,311

Attributed

$4,202,846

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $669.7K · FY2012–25

$1M$750K$500K$250K$0

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$4,202,846 · 5

By mechanism

R01$2,886,297 · 1

R43$894,674 · 3

R21$421,875 · 1

Top collaborators

Yanming Du6 shared
Stephan Menne6 shared
Xiaodong Xu2 shared
Minghong Zhong1 shared

Most similar at Enantigen Therapeutics, Inc.

Same institution · by research overlap

Xiaodong Xu$579,817

Others in their field

Top investigators on “Chronic Hepatitis B”

Judith S. Currier · University Of California Los Angeles$138,383,302
Joseph J. Eron · Univ Of North Carolina Chapel Hill$138,383,302
Steven H. Belle · University Of Pittsburgh At Pittsburgh$30,402,044
Robert M. Grant · J. David Gladstone Institutes$28,544,833
Charles M. Rice · Rockefeller University$22,084,027
David R. Milich · Immune Complex Corporation$18,253,778

Research focus

Chronic Hepatitis BFda ApprovedDna BiosynthesisIn VitroPharmaceutical PreparationsIn VivoVirus ReplicationViral DnaHepatocyteDna Polymerase InhibitorPre-ClinicalHepatitis B VirusCircular DnaModificationHepatoma CellMolecularTherapeutic EvaluationAnimal ModelTranscriptional RegulationLeadMetabolismAntiviral AgentsComplexImmune